Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Sangamo issues $996k in stock, to pay earn-outs for gene therapy firm Ceregene

Executive Summary

Sangamo BioSciences Inc. (protein medicines targeting DNA) has acquired Ceregene Inc., a private gene therapeutics developer. Sangamo is issuing 100k shares valued at $996k up front, representing less than 0.2% of its outstanding stock. Ceregene may also receive a certain amount of cash and cash equivalent minus certain liabilities and expenses.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Acquisition of Private Biotech
    • Payment Includes Cash
    • Payment Includes Stock
    • Includes Earnout
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register